Ney Carter Borges: Ticagrelor vs Prasugrel After PCI in Patients With Diabetes and MCAD
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Ticagrelor vs Prasugrel After PCI in Patients With Diabetes and Multivessel Coronary Artery Disease
Patients with diabetes mellitus undergoing percutaneous coronary intervention (PCI) represent a particularly high-risk population due to enhanced platelet reactivity, increased thrombotic burden, and a greater incidence of recurrent ischemic events.
Potent P2Y12 inhibitors are therefore recommended as part of dual antiplatelet therapy (DAPT) following PCI. A recent randomized multicenter study evaluated the comparative clinical outcomes of ticagrelor versus prasugrel in patients with diabetes and multivessel coronary artery disease undergoing PCI with drug-eluting stents.
The trial enrolled approximately 1,800 patients across multiple centers between 2020 and 2024. Participants had documented diabetes mellitus and angiographically confirmed multivessel coronary artery disease requiring PCI. Patients were randomized to receive either ticagrelor (90 mg twice daily) or prasugrel (10 mg once daily), both administered in combination with aspirin as standard DAPT.
The primary endpoint was a composite of all-cause death, myocardial infarction, stroke, or major bleeding within 12 months after PCI. The composite endpoint occurred in 16.6% of patients treated with ticagrelor compared with 14.2% of those receiving prasugrel, corresponding to a relative risk of 1.17 (95% CI 0.95–1.44; p = 0.12).
Ticagrelor therefore failed to demonstrate non-inferiority compared with prasugrel. Individual clinical events, including death and myocardial infarction, were numerically lower in the prasugrel group, although differences were not statistically significant when analyzed separately.
These findings suggest that prasugrel may provide slightly more favorable outcomes in diabetic patients with complex coronary disease undergoing PCI. The results reinforce the concept that potent platelet inhibition strategies may not be fully interchangeable in high-risk populations. While both agents remain guideline-supported options for DAPT after PCI, this study highlights a potential clinical advantage of prasugrel in patients with diabetes and multivessel coronary artery disease.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Mar 24, 2026, 16:46Emmanuel J Favaloro: Ensuring Worldwide Access and Supply of Anticoagulants
-
Mar 24, 2026, 16:44Robert Talac: Is PRP Truly Autologous?
-
Mar 24, 2026, 16:44Daniel Adunkwah: Reimagining Safety and Choice with Autologous Blood Transfusions
-
Mar 24, 2026, 16:42Peter Jaworski: The Shift in Plasma Center Locations Is About Demand, Not Economics
-
Mar 24, 2026, 16:41Apolipoprotein C3 as A Paradoxical Inhibitor of Platelet Aggregation and Thrombosis – JTH
-
Mar 24, 2026, 16:38Chris Centeno: Can Platelet Concentration Be Back-Calculated from Blood Draw Volume as a Surrogate?
-
Mar 24, 2026, 16:33Gaetan Duport: The Next Challenge for Patient Involvement at EMA
-
Mar 24, 2026, 16:27ABL Tyrosine Kinase Inhibitors Linked to Arterial Thrombosis – Blood Journals Portfolio
-
Mar 24, 2026, 16:21Wolfgang Miesbach: Infections as a Trigger for Stroke in Young Adults